Stephan Schann

Chief Tech/Sci/R&D Officer at Domain Therapeutics SA

Health Technology

Consumer Services

Commercial Services

Profile

Stephan Schann is currently the Chief Scientific Officer at Domain Therapeutics SA since 2008.
He previously worked as a Team Leader at Evotec (UK) Ltd.
Dr. Schann obtained his graduate and doctorate degrees from the University of Strasbourg.

Stephan Schann active positions

Companies	Position	Start
Domain Therapeutics SA Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.	Chief Tech/Sci/R&D Officer	2007-12-31

All active positions of Stephan Schann

Former positions of Stephan Schann

Companies	Position	End
Evotec (UK) Ltd. Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991.	Corporate Officer/Principal	-

See the detail of Stephan Schann's experience

Training of Stephan Schann

University of Strasbourg

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Stephan Schann's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Domain Therapeutics SA Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.	Health Technology
Evotec (UK) Ltd. Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991.	Commercial Services